These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 11426641)

  • 1. Design of growth factor antagonists with antiangiogenic and antitumor properties.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6566-73. PubMed ID: 11426641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice.
    Blaskovich MA; Lin Q; Delarue FL; Sun J; Park HS; Coppola D; Hamilton AD; Sebti SM
    Nat Biotechnol; 2000 Oct; 18(10):1065-70. PubMed ID: 11017044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors.
    Sun J; Wang DA; Jain RK; Carie A; Paquette S; Ennis E; Blaskovich MA; Baldini L; Coppola D; Hamilton AD; Sebti SM
    Oncogene; 2005 Jul; 24(29):4701-9. PubMed ID: 15897913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
    Morin MJ
    Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress.
    Renhowe PA
    Curr Opin Drug Discov Devel; 2002 Mar; 5(2):214-24. PubMed ID: 11926128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation.
    Zhou H; Wang DA; Baldini L; Ennis E; Jain R; Carie A; Sebti SM; Hamilton AD
    Org Biomol Chem; 2006 Jun; 4(12):2376-86. PubMed ID: 16763682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases.
    Mazitschek R; Giannis A
    Curr Opin Chem Biol; 2004 Aug; 8(4):432-41. PubMed ID: 15288254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
    Griffin RJ; Williams BW; Wild R; Cherrington JM; Park H; Song CW
    Cancer Res; 2002 Mar; 62(6):1702-6. PubMed ID: 11912143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
    Pietras K; Rubin K; Sjöblom T; Buchdunger E; Sjöquist M; Heldin CH; Ostman A
    Cancer Res; 2002 Oct; 62(19):5476-84. PubMed ID: 12359756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.
    Dai Y
    Expert Opin Ther Pat; 2010 Jul; 20(7):885-97. PubMed ID: 20509775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
    Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ
    Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
    George D
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
    Emanuel S; Gruninger RH; Fuentes-Pesquera A; Connolly PJ; Seamon JA; Hazel S; Tominovich R; Hollister B; Napier C; D'Andrea MR; Reuman M; Bignan G; Tuman R; Johnson D; Moffatt D; Batchelor M; Foley A; O'Connell J; Allen R; Perry M; Jolliffe L; Middleton SA
    Mol Pharmacol; 2004 Sep; 66(3):635-47. PubMed ID: 15322256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.